GINA Goes to School

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.

Although there are many objections to EEOC proposed changes, some in the business community want more liberal regulations around wellness program inducements.

Not Even Then

A jury awards $2.25 million in the case of the 'devious defecator,' which was brought under the US Genetic Information Nondiscrimination Act.

The case of the 'devious defecator' examines the protections of the Genetic Information Nondiscrimination Act.

Almost seven years after the Genetic Information Nondiscrimination Act was signed into law, it has only been cited in a limited number of cases.

This article has been updated to clarify comments from Anya Prince of the Cancer Legal Resource Center. The article inaccurately cited Prince as stating that some states mandate coverage for BRCA testing.

Pittsburgh Technical Institute is the first Highmark customer that has agreed to offer the genetic testing service to its employees. The offering will not be a covered benefit under Highmark's health plans.

Although the three bills aren't exactly alike in scope, they reflect a growing sentiment at the state level that existing protections under the federal Genetic Information Non-discrimination Act don't go far enough when it comes to protecting individuals' genetic data from misuse.

A Cogent Research study of 1,000 US residents found decreasing interest in pharmacogenomics applications compared to previous years, while the number of respondents who fear that their genomic data could be used against them is on the rise.


An analysis of UK Biobank data finds hemochromatosis to be more prevalent than thought, according to the BBC.

An analysis finds that female biomedical researchers receive fewer prizes than male ones, and when they do win prizes, they are less prestigious.

In Nature this week: improved genomic analysis using a graph genome reference, tumor mutational burden could predict clinical response to immune checkpoint inhibitors, and more.

Federal researchers tell the Los Angeles Times that the shutdown is causing missed research opportunities as they try to keep their experiments going.